Henry Schein, Inc. (FRA:HS2)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.24B +19.6% |
| Revenue (ttm) | 11.93B +6.5% |
| Net Income | 353.35M +3.6% |
| EPS | 3.01 +10.3% |
| Shares Out | n/a |
| PE Ratio | 23.33 |
| Forward PE | 14.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 73.50 |
| Previous Close | 75.00 |
| Day's Range | 73.50 - 73.50 |
| 52-Week Range | 52.42 - 78.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Henry Schein
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, di... [Read more]
Financial Performance
In 2025, Henry Schein's revenue was $13.18 billion, an increase of 4.03% compared to the previous year's $12.67 billion. Earnings were $398.00 million, an increase of 2.05%.
Financial numbers in USD Financial StatementsNews
Henry Schein Transcript: 2026 Global Healthcare Conference
Leadership outlined priorities of accelerating growth, simplifying operations, and increasing rigor, with a $200 million operating income improvement plan and double-digit EPS growth targeted. Dental and medical segments are growing, with strong performance in consumables, private label, and technology. Capital allocation favors disciplined M&A and share buybacks.
Henry Schein, Applied BioCode enter distribution agreement
Applied BioCode announced a distribution agreement with Henry Schein (HSIC) to expand the availability of its BioCode MDx-3000 System and comprehensive molecular diagnostics menu. The BioCode MDx-3000...
Applied BioCode Announces Distribution Agreement with Henry Schein
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)-- #ClinicalDiagnostics--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services, to...
Henry Schein to Participate in Upcoming Investor Conference in September
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will presen...
Henry Schein price target raised to $110 from $100 at BTIG
BTIG analyst David Larsen raised the firm’s price target on Henry Schein (HSIC) to $110 from $100 and keeps a Buy rating on the shares as part of a broader…
Henry Schein price target raised to $100 from $86 at Barclays
Barclays raised the firm’s price target on Henry Schein (HSIC) to $100 from $86 and keeps an Overweight rating on the shares. The firm upped estimates citing the company’s “strong”…
Henry Schein price target raised to $104 from $97 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Henry Schein (HSIC) to $104 from $97 and keeps an Outperform rating on the shares. The company’s Q2 beat included…
Henry Schein price target raised to $109 from $97 at Baird
Baird analyst Jeff Johnson raised the firm’s price target on Henry Schein (HSIC) to $109 from $97 and keeps an Outperform rating on the shares. The firm updated its model…
Henry Schein price target raised to $86 from $82 at Mizuho
Mizuho analyst Steven Valiquette raised the firm’s price target on Henry Schein (HSIC) to $86 from $82 and keeps a Neutral rating on the shares.
Henry Schein price target raised to $94 from $89 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Henry Schein (HSIC) to $94 from $89 and keeps a Neutral rating on the shares. Henry Schein delivered a solid…
Henry Schein price target raised to $95 from $84 at Stifel
Stifel raised the firm’s price target on Henry Schein (HSIC) to $95 from $84 and keeps a Hold rating on the shares.
Henry Schein price target raised to $112 from $100 at Citi
Citi raised the firm’s price target on Henry Schein (HSIC) to $112 from $100 and keeps a Buy rating on the shares.
Henry Schein Earnings Call Transcript: Q2 2026
Q2 2026 saw strong sales and margin growth, with internal local currency sales up 4.6% and non-GAAP EPS up 15.5%. Full-year guidance was raised, driven by robust performance across dental, medical, and technology segments, and value creation initiatives remain on track.
Henry Schein Earnings release: Q2 2026
Henry Schein released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Henry Schein Slides: Q2 2026
Henry Schein has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Henry Schein Quarterly report: Q2 2026
Henry Schein has published its Q2 2026 quarterly earnings report on August 4, 2026.
Henry Schein Slides: Corporate presentation
Henry Schein has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
Henry Schein raises 2026 non-GAAP EPS view to $5.29-$5.39 from $5.23-$5.37
2026 EPS consensus $5.34. Raises 2026 revenue growth view to 4.5%-5.5% from 3%-5%, consensus $13.75B. 2025 revenue was $13.18B.
Henry Schein reports Q2 non-GAAP EPS $1.27 , consensus $1.24
Reports Q2 revenue $3.5B, consensus $3.37B. “We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operationa...
Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial resu...
Henry Schein Stock (HSIC) Falls as Three Senior Executives Leave the Company
The stock has been treading water for five years.
Henry Schein creates HSLT, announces leadership transitions
Henry Schein (HSIC) announced that it is creating the Henry Schein Leadership Team, HSLT, to replace its Executive Management Committee. The Company will also integrate its global supply chain organiz...
Henry Schein Announces Leadership Transitions
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that it is creating the Henry Schein Leadership Team (HSLT) to replace its Executive Management Committee. The Compan...
Henry Schein price target raised to $95 from $91 at Piper Sandler
Piper Sandler analyst Jason Bednar raised the firm’s price target on Henry Schein (HSIC) to $95 from $91 and keeps an Overweight rating on the shares. The firm notes Henry…
Henry Schein price target raised to $89 from $85 at UBS
UBS raised the firm’s price target on Henry Schein (HSIC) to $89 from $85 and keeps a Neutral rating on the shares.